GLG LLC’s Teva Pharmaceuticals TEVA Stock Holding History

GLG LLC’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-205,000	Closed	-$9.43M	–	545
2016 Q3	$9.43M	Buy	+205,000	New	+$10.7M	0.67%	36
2016 Q2	–	Sell	-78,445	Closed	-$4.2M	–	536
2016 Q1	$4.2M	Buy	78,445 +233	+0.3%	+$13.7K	0.26%	104
2015 Q4	$5.13M	Sell	78,212 -511,306	-87%	-$31.6M	0.31%	88
2015 Q3	$33.3M	Sell	589,518 -1,557	-0.3%	-$101K	0.83%	30
2015 Q2	$34.9M	Buy	+591,075	New	+$36.5M	0.74%	32

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

GLG LLC's TEVA Position: Q4 2016 in Review

GLG LLC sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 205,000 shares — an estimated $9.43M sold.

GLG LLC first reported a position in TEVA in Q2 2015 and held it in 5 quarters. The position peaked at $34.9M in Q2 2015. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

GLG LLC reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
GLG LLC sold 205,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $9.43M.
GLG LLC first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 5 quarters.
GLG LLC's Teva Pharmaceuticals position peaked at $34.9M in Q2 2015.
739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on GLG LLC's 13F filing for Q4 2016, filed 14 Feb 2017.